SAIRIYO THERAPEUTICS
Sairiyo is a biotechnology company focused on repurposing and developing improved formulations of naturally derived compounds for serious, rare, and life-threatening diseases with the aim to obtain European Medicines Evaluation Agency and U.S. Food and Drug Administration ("FDA") approval.
SAIRIYO THERAPEUTICS
Industry:
Biopharma Biotechnology Health Care
Address:
Toronto, Ontario, Canada
Country:
Canada
Status:
Active
More informations about "Sairiyo Therapeutics"
Sairiyo Therapeutics Company Profile 2024: Valuation, Investors ...
Sairiyo Therapeutics General Information Description. Developer of improved formulations of naturally derived compounds for serious, rare and life-threatening diseases.See details»
Pharmadrug Inc
PharmaDrug owns 51% of Sairiyo Therapeutics (“Sairiyo”), a biotech company that specializes in researching and reformulating established natural medicines with a goal of bringing them …See details»
Sairiyo Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Explore Sairiyo Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 42 news, Drug:Cepharanthine.See details»
Sairiyo Therapeutics - Pharmadrug Inc
Developing Novel Therapeutics For Serious Rare and Life-Threatening Diseases. Sairiyo Therapeutics is focused on repurposing and developing improved formulations of naturally derived compounds for serious, rare, and life …See details»
PharmaDrug Completes Acquisition of Sairiyo Therapeutics Inc.
Feb 2, 2021 Sairiyo has an exclusive license from a research and development organization to develop and commercialize reformulated Cepharanthine for all diseases and exclusive rights …See details»
Sairiyo Therapeutics - Products, Competitors, Financials, …
Sairiyo Therapeutics is a biotechnology company focused on repurposing and developing improved formulations of naturally derived compounds for serious, rare, and life-threatening …See details»
Sairiyo Therapeutics Company Profile | Management and
Sairiyo Therapeutics Profile and History Sairiyo is a biotechnology company focused on repurposing and developing improved formulations of naturally derived compounds for serious, …See details»
Sairiyo Therapeutics - Overview, News & Similar companies
Mar 3, 2021 Who is Sairiyo Therapeutics. Sairiyo is a biotechnology company focused on repurposing and developing improved formulations of naturally derived compounds for serious, …See details»
Pharmadrug Inc
As announced on August 19, 2024, Sairiyo Therapeutics Inc. (“Sairiyo”), a company that is fifty-one percent (51%) owned by PharmaDrug and fourty-nine percent (49%) owned by …See details»
Sairiyo Therapeutics, Inc.: Drug pipelines, Patents, Clinical trials ...
Aug 2, 2023 Explore Sairiyo Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 9 news.See details»
PharmaDrug's Sairiyo Therapuetics Announces Initiation of Study …
Sep 19, 2024 As announced on August 19, 2024, Sairiyo Therapeutics Inc ... scale-up of PD-001 and the evaluation and final selection of potential clinical sites and a clinical research …See details»
Recent Post - Pharmadrug Inc
PharmaDrug’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine. Toronto, Ontario – May 1, 2024 – …See details»
Press Releases Ketamine - PharmaTher Holdings Ltd. Ketamine
TORONTO, May 1, 2024 -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, announced today …See details»
PharmaDrug Announces LOI to Acquire Sairiyo Therapeutics Inc.
Jan 12, 2021 In clinical research, Cepharanthine exhibits multiple pharmacological properties including anti-oxidative, anti-inflammatory, immuno-regulatory, anti-cancer, anti-viral and anti …See details»
PharmaDrug Completes Acquisition of Sairiyo Therapeutics Inc.
Feb 2, 2021 Sairiyo has an exclusive license from a research and development organization to develop and commercialize reformulated Cepharanthine for all diseases and exclusive rights …See details»
PharmaDrug Enters Definitive Agreement for Acquisition of Sairiyo ...
Jan 25, 2021 Sairiyo is currently focused on advancing the clinical development of Cepharanthine to treat rare cancer diseases. Sairiyo recently received FDA orphan drug …See details»
Pharmadrug Inc
PharmaDrug Announces Strategic Investment in Sairiyo Therapeutics Inc. Toronto, Ontario – July 18, 2023 – PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (“PharmaDrug” or the …See details»
PharmaDrug’s Sairiyo To Begin Manufacturing PD-001 For Clinical …
Feb 14, 2024 The venture, referred to as Sairiyo Therapeutics, has seen a milestone in the development of Cepharanthine, also known as PD-001. PD-001 is a version of orally …See details»
Recent Post - Pharmadrug Inc
As announced on August 19, 2024, Sairiyo Therapeutics Inc. (“Sairiyo”), a company that is fifty-one percent (51%) owned by PharmaDrug and fourty-nine percent (49%) owned by …See details»